Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

REGN

Regeneron Pharmaceuticals, Inc

Mar 21 • 04:00PM ET

658.48

Dollar change -4.14
Percentage change -0.62	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB GILD VRTX MRNA BMRN INCY EXEL IONS

| Held by: VTI VOO QQQ SPY IVV VTV XLV IBB JEPI VHT

Scroll to Statements

Index	NDX, S&P 500	P/E	17.20	EPS (ttm)	38.29	Insider Own	3.59%	Shs Outstand	107.80M	Perf Week	-1.26%
Market Cap	71.99B	Forward P/E	14.24	EPS next Y	46.26	Insider Trans	-0.05%	Shs Float	105.40M	Perf Month	-5.39%
Income	4.41B	PEG	2.82	EPS next Q	9.32	Inst Own	86.36%	Short Float	2.43%	Perf Quarter	-11.02%
Sales	14.20B	P/S	5.07	EPS this Y	-7.46%	Inst Trans	0.51%	Short Ratio	2.88	Perf Half Y	-42.18%
Book/sh	267.82	P/B	2.46	EPS next Y	9.57%	ROA	12.43%	Short Interest	2.57M	Perf Year	-31.67%
Cash/sh	82.44	P/C	7.99	EPS next 5Y	6.10%	ROE	15.95%	52W Range	642.00 - 1211.20	Perf YTD	-7.56%
Dividend Est.	2.83 (0.43%)	P/FCF	19.64	EPS past 5Y	15.74%	ROI	13.68%	52W High	-45.63%	Beta	0.41
Dividend TTM	0.88 (0.13%)	Quick Ratio	3.95	Sales past 5Y	22.10%	Gross Margin	82.73%	52W Low	2.57%	ATR (14)	21.25
Dividend Ex-Date	Feb 20, 2025	Current Ratio	4.73	EPS Y/Y TTM	10.35%	Oper. Margin	28.97%	RSI (14)	41.01	Volatility	2.03% 3.15%
Employees	15106	Debt/Eq	0.10	Sales Y/Y TTM	8.27%	Profit Margin	31.07%	Recom	1.75	Target Price	944.05
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-20.86%	Payout	0.00%	Rel Volume	2.09	Prev Close	662.62
Sales Surprise	1.25%	EPS Surprise	6.98%	Sales Q/Q	10.33%	Earnings	Feb 04 BMO	Avg Volume	891.98K	Price	658.48
SMA20	-4.81%	SMA50	-4.70%	SMA200	-27.22%	Trades		Volume	1,863,290	Change	-0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform	$762 → $834
Jan-16-25	Downgrade	UBS	Buy → Neutral	$1130 → $738
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150
Nov-14-24	Initiated	Citigroup	Neutral	$895
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform	$1175 → $1077
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$950
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy	$720 → $992
Aug-21-23	Reiterated	Oppenheimer	Perform	$950 → $1050
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold	$953 → $720
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform	$834 → $976
Mar-24-23	Upgrade	Jefferies	Hold → Buy	$675 → $925
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform	$775 → $875
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight	$850
Oct-26-22	Downgrade	Raymond James	Mkt Perform → Underperform
Oct-17-22	Downgrade	Evercore ISI	Outperform → In-line	$760

Show Previous Ratings

Today 05:06AM	3 Reasons to Sell REGN and 1 Stock to Buy Instead (StockStory)
Mar-20-25 12:30PM	Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug (Zacks)
09:20AM	Invesco American Franchise Fund Q4 2024 Commentary (SeekingAlpha)
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-18-25 05:38AM	Regeneron Pharmaceuticals (REGN): Among the Best Biotech Stocks to Buy According to Billionaires (Insider Monkey)
10:07PM	Loading…
Mar-17-25 10:07PM	Jim Cramer Wants You to 'Own' Regeneron Pharmaceuticals (REGN) Shares (Insider Monkey)
09:01AM	2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off (StockStory)
Mar-14-25 11:37AM	Jim Cramer On Regeneron Pharmaceuticals Inc. (REGN) I Want You to Own It (Insider Monkey)
Mar-13-25 07:22AM	3 Stocks With Ironclad Balance Sheets for Long-Term Stability (MarketBeat)
Mar-12-25 02:29PM	Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Pharma Stock to Buy According to Hedge Funds? (Insider Monkey)
Mar-11-25 10:50PM	Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem (PR Newswire)
09:32PM	Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem (GlobeNewswire)
Mar-10-25 07:29PM	Regeneron Pharmaceuticals, Inc. (REGN): Hedge Funds Are Bullish On This Oversold Blue Chip Stock Now (Insider Monkey) +5.27%
05:33PM	S&P 500 Gains and Losses Today: Index Tumbles as Economic Concerns Intensify (Investopedia)
Mar-09-25 06:20AM	1 Dividend Stock Down 30% to Buy and Hold for the Next Decade (Motley Fool)
01:00PM	Loading…
Mar-08-25 01:00PM	Dupixent (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD (GlobeNewswire)
Mar-06-25 11:31AM	Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report? (Zacks)
Mar-04-25 05:27AM	Is Regeneron Pharmaceuticals, Inc. (REGN) the Worst Performing Large Cap Stock to Buy According to Analysts? (Insider Monkey)
Mar-03-25 10:32AM	Regeneron's (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices- Hagens Berman (Newsfile)
Feb-28-25 07:00AM	Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Feb-27-25 08:42AM	Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman (Newsfile)
07:17AM	Regeneron makes second bid for blood cancer therapy approval (Pharmaceutical Technology)
Feb-26-25 07:00AM	Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma (GlobeNewswire)
Feb-25-25 12:26PM	Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts (Insider Monkey)
03:30AM	Regeneron gene therapy helps deaf children hear in small study (BioPharma Dive)
Feb-24-25 03:00PM	Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial (GlobeNewswire)
12:46PM	Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts (Insider Monkey)
Feb-21-25 08:00AM	2 Healthcare Stocks with Big Upside and 1 to Skip (StockStory)
Feb-20-25 10:40AM	Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman (Newsfile)
Feb-18-25 11:27AM	FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea (Investopedia)
09:45AM	Loading…
09:45AM	This Company Just Initiated a Quarterly Dividend: Time to Buy? (Motley Fool)
07:17AM	FDA to review Sanofi and Regenerons Dupixent sBLA for bullous pemphigoid (Pharmaceutical Technology)
12:59AM	Dupixent (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP) (GlobeNewswire)
Feb-14-25 05:45AM	Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN (PR Newswire)
Feb-11-25 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
07:00AM	Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
05:45AM	Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN (PR Newswire)
Feb-10-25 11:21AM	Regenerons macular oedema therapy shows promise in Phase III trial (Clinical Trials Arena)
06:15AM	Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move (Motley Fool)
Feb-09-25 08:02AM	Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow (StockStory)
Feb-08-25 05:40PM	EYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting (GlobeNewswire)
03:55PM	Three-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals (GlobeNewswire)
Feb-07-25 08:44PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Feb-06-25 11:00AM	Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit- Hagens Berman (Newsfile)
Feb-05-25 06:28AM	Amgen obesity drug on hold; Regeneron sets first dividend (BioPharma Dive)
02:07AM	Regeneron Pharmaceuticals Inc (REGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
01:25AM	Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-04-25 06:44PM	Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday (Motley Fool)
06:27PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
04:11PM	Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend (Investor's Business Daily)
01:20PM	MAIAs lung cancer therapy 99% more likely to improve OS over chemo alone (Clinical Trials Arena)
12:02PM	Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program (Benzinga)
09:35AM	Is Regeneron Pharmaceuticals (REGN) the Best Cancer Stock to Buy According to Hedge Funds? (Insider Monkey)
09:30AM	Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics (Zacks)
08:56AM	Regeneron Advances On Fourth-Quarter Beat As Eylea Meets Expectations (Investor's Business Daily)
08:15AM	Regeneron beats quarterly estimates on eczema drug demand; launches dividend program (Reuters)
07:45AM	Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates (Zacks)
06:54AM	Regeneron: Q4 Earnings Snapshot (Associated Press Finance)
06:46AM	Regenerons (NASDAQ:REGN) Q4 Sales Top Estimates, Stock Soars (StockStory)
06:30AM	Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion (GlobeNewswire)
Feb-02-25 07:51AM	Why Are Analysts Bullish on Regeneron Pharmaceuticals, Inc. (REGN) Now? (Insider Monkey)
Jan-31-25 09:15AM	Ahead of Regeneron (REGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Jan-30-25 06:20AM	Sanofi Expects Strong Earnings Growth This Year, Plans $5.2 Billion Buyback (The Wall Street Journal)
Jan-28-25 03:00PM	Drugmakers Show Restraint on Price Increases in New Trump Era (The Wall Street Journal)
10:00AM	Earnings Preview: Regeneron (REGN) Q4 Earnings Expected to Decline (Zacks)
08:46AM	Implied Volatility Surging for Regeneron Pharmaceuticals (REGN) Stock Options (Zacks)
08:27AM	Is Regeneron Pharmaceuticals (REGN) Among the Best Depressed Stocks to Invest in Now? (Insider Monkey)
Jan-27-25 04:59PM	Is Regeneron Pharmaceuticals (REGN) the Best Stock to Buy and Hold for 2025? (Insider Monkey)
Jan-24-25 07:38AM	Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Falling Stock to Invest in Right Now? (Insider Monkey)
05:45AM	Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN (PR Newswire)
Jan-23-25 12:02PM	America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search (PR Newswire)
Jan-21-25 02:35PM	REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES (PR Newswire)
Jan-19-25 06:17AM	Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): This Company Has Never Lost Its Ability To Develop New Medicines (Insider Monkey)
Jan-17-25 05:45AM	Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN (PR Newswire)
Jan-16-25 12:54PM	Pharma giant Regeneron is spending $119.5M on the worlds largest, most diverse genetic database using DNA from patient volunteers (Fortune)
11:28AM	UBS cuts rating on Regeneron stock amid Eylea uncertainty (Investing.com)
Jan-15-25 11:29AM	Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): Stock That Seems To Have Disappointed People. Bizarre (Insider Monkey)
Jan-13-25 04:17PM	Regeneron Culls Losses After High-Dose Eylea Sales Disappoint (Investor's Business Daily)
12:25PM	Illumina and Regeneron invest $139.5m in Truveta to build largest genetic database (Medical Device Network)
09:23AM	Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint (Investor's Business Daily)
06:30AM	Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
06:15AM	Adjuvant Libtayo (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial (GlobeNewswire)
06:07AM	Truveta sells stakes to Regeneron, Illumina in deal to build genetic database (Reuters)
06:05AM	Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery (GlobeNewswire)
Jan-10-25 12:10PM	Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again (Zacks) -5.00%
Jan-07-25 04:05PM	Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025 (GlobeNewswire)
Jan-06-25 08:07AM	Ultragenyxs Evkeeza secures EU approval for young children with rare cholesterol disorder (Pharmaceutical Technology)
Jan-02-25 10:00AM	1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street (Motley Fool)
Jan-01-25 12:37PM	Jim Cramers Take on Regeneron Pharmaceuticals (REGN): Bold Predictions for the Future (Insider Monkey)
Dec-19-24 07:23AM	Regeneron says study data support big bet on new blood thinners (BioPharma Dive)
07:00AM	Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results (GlobeNewswire)
Dec-18-24 09:39PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
Dec-17-24 04:05PM	Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:34AM	Bayers Eye Drug Shows Positive Results in Late-Stage Trial (The Wall Street Journal)
07:00AM	EYLEA HD (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion (GlobeNewswire)
06:53AM	Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-16-24 04:30PM	Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year (GlobeNewswire)
Dec-13-24 07:19AM	Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge (Pharmaceutical Technology)
Dec-12-24 02:26AM	Regenerons R&D approach scores dual wins against Alexions Ultomiris and in lymphoma (Pharma Voice)
Dec-11-24 01:19PM	Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900 (Insider Monkey)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SING GEORGE L	Director	Dec 31 '24	Option Exercise	413.33	3,338	1,379,696	29,610	Jan 03 04:02 PM
McCourt Marion	EVP Commercial	Nov 01 '24	Option Exercise	381.40	1,000	381,400	13,931	Nov 05 04:23 PM
McCourt Marion	EVP Commercial	Nov 01 '24	Sale	844.61	1,000	844,610	12,931	Nov 05 04:23 PM
MARION E MCCOURT	Officer	Nov 01 '24	Proposed Sale	844.61	1,000	844,610		Nov 01 04:38 PM
RYAN ARTHUR F	Director	Oct 01 '24	Sale	1048.78	100	104,878	17,582	Oct 03 04:02 PM
McCourt Marion	EVP Commercial	Oct 01 '24	Option Exercise	381.40	1,000	381,400	13,931	Oct 03 04:02 PM
McCourt Marion	EVP Commercial	Oct 01 '24	Sale	1054.06	1,000	1,054,060	12,931	Oct 03 04:02 PM
MARION E MCCOURT	Officer	Oct 01 '24	Proposed Sale	1054.06	1,000	1,054,060		Oct 01 04:13 PM
McCourt Marion	EVP Commercial	Sep 03 '24	Option Exercise	381.40	1,000	381,400	13,931	Sep 05 04:01 PM
McCourt Marion	EVP Commercial	Sep 03 '24	Sale	1178.73	1,000	1,178,730	12,931	Sep 05 04:01 PM
RYAN ARTHUR F	Director	Sep 03 '24	Sale	1178.68	100	117,868	17,682	Sep 05 04:01 PM
MARION E MCCOURT	Officer	Sep 03 '24	Proposed Sale	1178.73	1,000	1,178,730		Sep 03 04:04 PM
Fenimore Christopher R.	SVP Finance & CFO	Aug 28 '24	Sale	1205.33	5,680	6,846,262	0	Aug 29 04:27 PM
Christopher Fenimore	Officer	Aug 28 '24	Proposed Sale	1205.21	5,680	6,845,565		Aug 28 04:35 PM
Bassler Bonnie L	Director	Aug 15 '24	Option Exercise	371.40	756	280,778	2,138	Aug 19 04:02 PM
Bassler Bonnie L	Director	Aug 15 '24	Sale	1170.00	756	884,520	1,382	Aug 19 04:02 PM
POON CHRISTINE A	Director	Aug 15 '24	Option Exercise	413.33	10,838	4,479,671	13,010	Aug 19 04:01 PM
POON CHRISTINE A	Director	Aug 15 '24	Sale	1158.17	10,838	12,552,284	2,172	Aug 19 04:01 PM
Christine Poon	Director	Aug 15 '24	Proposed Sale	1156.86	10,838	12,538,049		Aug 15 05:55 PM
MURPHY ANDREW J	EVP Research	Aug 13 '24	Option Exercise	399.66	20,000	7,993,200	68,306	Aug 15 04:01 PM
MURPHY ANDREW J	EVP Research	Aug 14 '24	Sale	1153.15	6,363	7,337,505	48,306	Aug 15 04:01 PM
Bassler Bonnie L	Director	Aug 15 '24	Proposed Sale	1170.00	756	884,520		Aug 15 11:45 AM
MURPHY ANDREW J	Officer	Aug 14 '24	Proposed Sale	1152.27	6,363	7,331,894		Aug 14 04:08 PM
STAHL NEIL	EVP Research and Development	Aug 08 '24	Sale	1084.54	5,197	5,636,346	50,999	Aug 12 04:05 PM
Neil Stahl	Officer	Aug 08 '24	Proposed Sale	1084.46	5,197	5,635,926		Aug 08 04:53 PM
Pitofsky Jason	VP Controller	Aug 07 '24	Option Exercise	372.46	487	181,388	4,691	Aug 07 04:40 PM
Pitofsky Jason	VP Controller	Aug 07 '24	Sale	1070.00	487	521,090	4,204	Aug 07 04:40 PM
Jason Pitofsky	Officer	Aug 07 '24	Proposed Sale	1069.75	487	520,970		Aug 07 04:33 PM
STAHL NEIL	EVP Research and Development	Aug 02 '24	Option Exercise	555.67	23,638	13,134,927	74,637	Aug 06 04:03 PM
Bassler Bonnie L	Director	Aug 02 '24	Option Exercise	371.40	756	280,778	2,138	Aug 05 04:05 PM
Bassler Bonnie L	Director	Aug 02 '24	Sale	1115.00	756	842,940	1,382	Aug 05 04:05 PM
McCourt Marion	EVP Commercial	Aug 01 '24	Option Exercise	372.46	1,137	423,487	14,068	Aug 05 04:04 PM
McCourt Marion	EVP Commercial	Aug 01 '24	Sale	1060.86	1,137	1,206,198	12,931	Aug 05 04:04 PM
RYAN ARTHUR F	Director	Aug 01 '24	Sale	1100.03	1	1,100	17,782	Aug 05 04:01 PM
RYAN ARTHUR F	Director	Aug 01 '24	Sale	1085.53	99	107,467	17,783	Aug 05 04:01 PM
Bassler Bonnie L	Director	Aug 02 '24	Proposed Sale	1115.00	756	842,940		Aug 02 10:43 AM
MARION E MCCOURT	Officer	Aug 01 '24	Proposed Sale	1060.86	1,137	1,206,198		Aug 01 04:18 PM
Arthur F. Ryan	Director	Aug 01 '24	Proposed Sale	1079.19	300	323,757		Aug 01 04:02 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Jul 11 '24	Sale	1088.95	1,866	2,031,981	37,937	Jul 12 04:00 PM
McCourt Marion	EVP Commercial	Jul 01 '24	Option Exercise	372.46	1,137	423,487	14,068	Jul 02 04:01 PM
McCourt Marion	EVP Commercial	Jul 01 '24	Sale	1047.11	1,137	1,190,564	12,931	Jul 02 04:01 PM
RYAN ARTHUR F	Director	Jul 01 '24	Sale	1059.24	100	105,924	17,882	Jul 02 04:01 PM
Bassler Bonnie L	Director	Jun 24 '24	Option Exercise	371.40	756	280,778	2,138	Jun 25 04:41 PM
Bassler Bonnie L	Director	Jun 24 '24	Sale	1062.00	756	802,872	1,382	Jun 25 04:41 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Jun 24 '24	Option Exercise	555.67	14,450	8,029,431	50,887	Jun 25 04:39 PM
BROWN MICHAEL S	Director	Jun 14 '24	Option Exercise	625.60	1,535	960,296	2,917	Jun 17 04:01 PM
BROWN MICHAEL S	Director	Jun 14 '24	Sale	1040.00	1,535	1,596,400	1,382	Jun 17 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 12 '24	Sale	1015.94	16,149	16,406,406	0	Jun 13 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 11 '24	Sale	1015.43	9,064	9,203,823	55,134	Jun 13 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 06 '24	Sale	1015.02	787	798,821	64,198	Jun 10 04:03 PM
Bassler Bonnie L	Director	Jun 05 '24	Option Exercise	380.95	827	315,046	2,209	Jun 07 04:06 PM
Bassler Bonnie L	Director	Jun 05 '24	Sale	1011.00	827	836,097	1,382	Jun 07 04:06 PM
McCourt Marion	EVP Commercial	Jun 03 '24	Option Exercise	372.46	1,138	423,859	14,069	Jun 05 04:07 PM
McCourt Marion	EVP Commercial	Jun 03 '24	Sale	980.16	1,138	1,115,422	12,931	Jun 05 04:07 PM
RYAN ARTHUR F	Director	Jun 03 '24	Sale	994.50	100	99,450	17,982	Jun 05 04:06 PM
BROWN MICHAEL S	Director	May 28 '24	Option Exercise	625.60	1,172	733,203	2,554	May 29 04:01 PM
BROWN MICHAEL S	Director	May 28 '24	Sale	974.86	1,172	1,142,536	1,382	May 29 04:01 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	May 21 '24	Sale	994.90	1,865	1,855,488	34,678	May 22 04:02 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 17 '24	Sale	979.23	22,830	22,355,714	466,877	May 17 05:57 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	May 16 '24	Sale	972.73	50,000	48,636,545	786,383	May 17 04:06 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	May 15 '24	Sale	975.87	50,000	48,793,727	836,383	May 17 04:04 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 13 '24	Option Exercise	399.66	203,204	81,212,511	577,633	May 15 06:10 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 14 '24	Sale	979.25	25,000	24,481,164	408,200	May 15 06:10 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 15 '24	Sale	980.34	10,941	10,725,946	397,259	May 15 06:10 PM
SING GEORGE L	Director	May 03 '24	Option Exercise	413.33	2,000	826,660	28,349	May 06 04:20 PM
McCourt Marion	EVP Commercial	May 01 '24	Sale	889.41	250	222,352	12,931	May 03 04:02 PM
RYAN ARTHUR F	Director	May 01 '24	Sale	899.61	100	89,961	18,082	May 03 04:01 PM
RYAN ARTHUR F	Director	Apr 01 '24	Sale	962.53	100	96,253	18,182	Apr 03 04:06 PM
McCourt Marion	EVP Commercial	Apr 01 '24	Sale	964.73	250	241,182	13,181	Apr 03 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REGN

Regeneron Pharmaceuticals, Inc

Upgrade your FINVIZ experience